Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of neoadjuvant chemotherapy with pelvic reirradiation versus chemotherapy alone for locally recurrent rectal cancer
2018-002833-39Phase 3Active
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jul 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of capecitabine, oxaliplatin, irinotecan, folinic acid and fluorouracil in rectal cancer (2 arms), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Proportion of curative surgery (R0 resection). Started Jul 2018; status: active.
02
Drugs
capecitabineoxaliplatinirinotecanfolinic acidfluorouracil
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2018-002833-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002833-39.